- Positive topline data from BDC-1001 dose-escalation clinical study validates the ability of the Boltbody™ ISAC platform to generate anti-tumor activity with acceptable safety
- BDC-1001 advances into a focused Phase 2 program commencing in 2023: a trial as monotherapy and in combination with nivolumab in colorectal, endometrial, and gastroesophageal cancers; and a second trial in breast cancer studying monotherapy and combination with pertuzumab (Perjeta®)
- BDC-3042 expected to enter clinic in 2023; upcoming presentation at AACR 2023
- Cash balance of $192.8 million anticipated to fund key milestones through 2025
REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.
“We believe the BDC-1001 Phase 1 results validate our Boltbody™ ISAC approach. Our design decisions enable us to deliver potent immune-stimulating antibody conjugates that can achieve positive clinical responses with acceptable tolerability, thereby, decoupling anti-tumor activity from the systemic safety issues that others have encountered. We are advancing into a thoughtfully designed, focused Phase 2 program evaluating BDC-1001 in patients with four different types of HER2-positive solid tumors where there remains important unmet medical need,” said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics.
“We are pleased to be entering into an agreement with Roche to supply pertuzumab in support of a new combination study with BDC-1001 and we look forward to investigating the impact of this combination in patients with HER2-positive metastatic breast cancer, while we continue to investigate BDC-1001 as monotherapy and work with our partner Bristol Myers Squibb to explore the combination with nivolumab. The progress in developing new immunotherapies in both our proprietary and partnered research programs demonstrates the potential of myeloid biology to provide important new treatment options to patients with cancer.”
Recent Highlights and Anticipated Milestones
- Topline BDC-1001 Phase 1 dose-escalation results – Topline data from a multi-center, multi-dose Phase 1 clinical trial evaluating BDC-1001 as a single agent and in combination with nivolumab supports selection of a recommended phase 2 dose (RP2D) and initiation of a Phase 2 clinical program including two studies in four tumor types.
- Phase 2 BDC-1001 studies planned to initiate in 2023 – Clinical trials will include patients with HER2-positive breast, colorectal, endometrial, and gastroesophageal cancers at clinical sites in the U.S., multiple European countries, and South Korea evaluating BDC-1001 as monotherapy, in combination with pertuzumab, and separately, in combination with nivolumab.
- BDC-3042 to enter the clinic in 2023 – Investigational New Drug (IND)-enabling activities for a Phase 1 trial for BDC-3042 are proceeding on track. BDC-3042 is an agonistic antibody targeting Dectin-2, an immune-activating receptor expressed by TAMs in solid tumors. Preclinical studies demonstrate the ability of Dectin-2 agonistic antibodies to reprogram tumor-associated macrophages and drive anti-tumor activity.
- Continued progress with Boltbody™ ISAC collaborations – Collaborations with Genmab and Innovent developing next-generation Boltbody ISACs continue to progress. Both collaborations are exploring proprietary linker-payloads from the Boltbody ISAC platform, combining with Genmab’s proprietary bispecific antibodies in one collaboration and with Innovent’s proprietary antibodies in the other.
- Strengthened Bolt's Board of Directors with appointment of Laura Berner – In December 2022, Laura Berner joined the Bolt Board of Directors. Ms. Berner brings extensive biopharmaceutical industry experience, having executed more than 50 transactions including research collaborations and product co-development and co-promotion partnerships. She currently serves as the Chief Operating Officer at TRexBio and has held multiple leadership positions spanning corporate strategy, business development, investor relations, and law.
- Cash, cash equivalents, and marketable securities were $192.8 million as of December 31, 2022 – Cash on hand, coupled with growing collaboration revenues, is expected to fund multiple key milestones and operations through 2025.
Upcoming Events
- BDC-3042 abstract accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, Fla.
Title: Targeting tumor-associated macrophages to enhance anti-tumor immunity with the Dectin-2 agonistic antibody
Poster Board Number: 11
Abstract Presentation Number: 2964
Presenter: Justin A. Kenkel, Ph.D.
Details: Monday, April 17, 2023, 1:30 p.m. – 5:00 p.m. EDT
Location: Orange County Convention Center, Section 24
Fourth Quarter and Full Year 2022 Financial Results
- Collaboration Revenue – Collaboration revenue was $1.4 million for the quarter and $5.7 million for the full year ended December 31, 2022, compared to $0.5 million and $1.3 million for the same quarter and year in 2021. The collaboration with Genmab exploring Boltbody ISACs using Genmab’s proprietary bispecific antibodies accounted for $4.2 million in revenue for 2022 and the collaboration with Innovent exploring Boltbody ISACs using Innovent’s proprietary antibodies accounted for $1.5 million in revenue for 2022.
- Research and Development (R&D) Expenses – R&D expenses were $16.8 million for the quarter and $73.1 million for the full year ended December 31, 2022, compared to $22.5 million and $75.7 million for the same quarter and year in 2021. The decrease in R&D expenses was due to lower manufacturing expenses related to the timing of batch production of our product candidates, offset by higher clinical expenses related to the ongoing BDC-1001 clinical trial due to increase in patient activities.
- General and Administrative (G&A) Expenses – G&A expenses were $5.6 million for the quarter and $22.9 million for the full year ended December 31, 2022, compared to $5.1 million and $18.4 million for the same quarter and year in 2021. The increase in G&A expenses was due to higher personnel-related expenses due to an increase in headcount and higher office and facility-related expenses, offset by lower consulting and professional services expenses.
- Loss from Operations – Loss from operations was $21.0 million for the quarter and $90.3 million for the full year ended December 31, 2022, compared to $27.1 million and $92.8 million for the same quarter and year in 2021.
About the Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) Platform
Bolt Biotherapeutics’ Boltbody ISAC platform unites the precision of antibodies with the power of the innate and adaptive immune system to reprogram the tumor microenvironment to generate a productive anti-cancer response. Each Boltbody ISAC candidate comprises a tumor-targeting antibody, a non-cleavable linker, and a proprietary immune stimulant. The antibody is designed to target one or more markers on the surface of a tumor cell and the immune stimulant is designed to recruit and activate myeloid cells. Activated myeloid cells initiate a positive feedback loop by releasing cytokines and chemokines, chemical signals that attract other immune cells and lower the activation threshold for an immune response. This increases the population of activated immune system cells in the tumor microenvironment and promotes a robust immune response, with the goal of generating durable therapeutic responses for patients with cancer.
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. BDC-1001 has completed a Phase 1 dose-escalation study demonstrating tolerability and early clinical efficacy, and the Company plans to initiate Phase 2 studies in 2023. Bolt Biotherapeutics is advancing BDC-3042, an agonist antibody targeting Dectin-2, through IND-enabling activities and expects to initiate a Phase 1 trial in the second half of 2023. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. Bolt Biotherapeutics is leveraging its ability to engineer and optimize novel applications of its Boltbody ISACs to develop multiple immuno-oncology candidates through strategic collaborations with leading biopharmaceutical companies. For more information, please visit https://www.boltbio.com/
Forward-Looking Statements
This press release contains forward-looking statements about us and our industry that involve substantial risks and uncertainties and are based on our beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts contained in this press release, including statements regarding our clinical trials, the timing of the completion of our monotherapy and combination dose escalation arms, the selection of a recommended Phase 2 dose for BDC-1001 for the treatment of patients with HER2-expressing solid tumors, our Phase 2 dose-expansion study design, the timing of our initiation of clinical development of BDC-3042, the resulting ISAC programs from our collaborations with Genmab A/S and Innovent Biologics, Inc., the success of our clinical collaborations and the ability of our clinical collaboration partners to supply nivolumab and pertuzumab (Perjeta®), our ability to fund our clinical programs and the sufficiency of our cash, cash equivalents, and marketable securities, expectations for growing collaboration revenues, our future results of operations, financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “on track,” “plan,” “potential,” “predict,” “project,” “should,” “will,” or “would,” or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our current beliefs, estimates and assumptions only as of the date of this press release and information contained in this press release should not be relied upon as representing our estimates as of any subsequent date. These statements, and related risks, uncertainties, factors and assumptions, include, but are not limited to: the potential product candidates that we develop may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; such product candidates may not be beneficial to patients or become commercialized; and our ability to maintain our current collaborations and establish further collaborations. These risks are not exhaustive. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Further information on factors that could cause actual results to differ materially from the results anticipated by our forward-looking statements is included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2022. These filings, when available, are available on the investor relations section of our website at investors.boltbio.com and on the SEC’s website at www.sec.gov.
Opdivo® is a trademark of Bristol-Myers Squibb Company.
Perjeta® is a trademark of Roche
| BOLT BIOTHERAPEUTICS, INC. STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited, in thousands, except share and per share amounts) | ||||||||||||||||
| For The Three Months Ended December 31, | Years Ended December 31, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Collaboration revenue | $ | 1,411 | $ | 508 | $ | 5,729 | $ | 1,260 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 16,845 | 22,484 | 73,123 | 75,655 | ||||||||||||
| General and administrative | 5,606 | 5,099 | 22,927 | 18,393 | ||||||||||||
| Total operating expense | 22,451 | 27,583 | 96,050 | 94,048 | ||||||||||||
| Loss from operations | (21,040 | ) | (27,075 | ) | (90,321 | ) | (92,788 | ) | ||||||||
| Other income (expense), net | ||||||||||||||||
| Interest income | 1,043 | (82 | ) | 2,223 | 281 | |||||||||||
| Change in fair value of convertible preferred stock purchase right liability | — | — | — | (6,084 | ) | |||||||||||
| Total other income (expense), net | 1,043 | (82 | ) | 2,223 | (5,803 | ) | ||||||||||
| Net loss | (19,997 | ) | (27,157 | ) | (88,098 | ) | (98,591 | ) | ||||||||
| Net unrealized loss on marketable securities | 790 | (283 | ) | (598 | ) | (321 | ) | |||||||||
| Comprehensive loss | $ | (19,207 | ) | $ | (27,440 | ) | $ | (88,696 | ) | $ | (98,912 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.53 | ) | $ | (0.73 | ) | $ | (2.36 | ) | $ | (2.97 | ) | ||||
| Weighted-average shares outstanding, basic and diluted | 37,552,208 | 37,269,511 | 37,358,425 | 33,196,712 | ||||||||||||
| BOLT BIOTHERAPEUTICS, INC. BALANCE SHEETS (Unaudited, in thousands) | ||||||||
| December 31, | ||||||||
| 2022 | 2021 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 9,244 | $ | 27,383 | ||||
| Short-term investments | 159,644 | 158,836 | ||||||
| Prepaid expenses and other current assets | 3,858 | 2,941 | ||||||
| Total current assets | 172,746 | 189,160 | ||||||
| Property and equipment, net | 6,453 | 6,158 | ||||||
| Operating lease right-of-use assets | 22,072 | 24,445 | ||||||
| Restricted cash | 1,565 | 1,565 | ||||||
| Long-term investments | 23,943 | 85,348 | ||||||
| Other assets | 1,028 | 1,042 | ||||||
| Total assets | $ | 227,807 | $ | 307,718 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,594 | $ | 3,574 | ||||
| Accrued expenses and other current liabilities | 15,140 | 12,384 | ||||||
| Deferred revenue | 1,993 | 2,869 | ||||||
| Operating lease liabilities | 2,391 | 2,501 | ||||||
| Total current liabilities | 23,118 | 21,328 | ||||||
| Operating lease liabilities, net of current portion | 20,220 | 21,854 | ||||||
| Deferred revenue, non-current | 12,921 | 14,207 | ||||||
| Other long-term liabilities | 42 | 210 | ||||||
| Total liabilities | 56,301 | 57,599 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity: | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | — | — | ||||||
| Additional paid-in capital | 467,513 | 457,430 | ||||||
| Accumulated other comprehensive loss | (919 | ) | (321 | ) | ||||
| Accumulated deficit | (295,088 | ) | (206,990 | ) | ||||
| Total stockholders' equity | 171,506 | 250,119 | ||||||
| Total liabilities, convertible preferred stock, and stockholders' equity | $ | 227,807 | $ | 307,718 | ||||
| BOLT BIOTHERAPEUTICS, INC. STATEMENTS OF CASH FLOWS (Unaudited, in thousands) | ||||||||
| Years Ended December 31, | ||||||||
| 2022 | 2021 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | (88,098 | ) | $ | (98,591 | ) | ||
| Adjustments to reconcile net loss to net cash used | ||||||||
| in operating activities: | ||||||||
| Depreciation and amortization | 1,666 | 1,193 | ||||||
| Stock-based compensation expense | 9,576 | 8,500 | ||||||
| Accretion of premium/discount on short-term investments | 184 | 2,654 | ||||||
| Loss on disposal of property and equipment | — | 108 | ||||||
| Change in fair value of convertible preferred stock purchase right liability | — | 6,084 | ||||||
| Non-cash lease expense | 3,225 | 2,479 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Prepaid expenses and other assets | (903 | ) | (568 | ) | ||||
| Accounts payable and accrued expenses | 2,768 | 6,676 | ||||||
| Operating lease liabilities | (2,596 | ) | (1,179 | ) | ||||
| Deferred revenue | (2,162 | ) | 15,574 | |||||
| Other long-term liabilities | (164 | ) | 4 | |||||
| Net cash used in operating activities | (76,504 | ) | (57,066 | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchase of property and equipment | (1,953 | ) | (2,338 | ) | ||||
| Purchases of marketable securities | (180,704 | ) | (313,375 | ) | ||||
| Maturities of marketable securities | 240,519 | 83,512 | ||||||
| Net cash provided by (used in) investing activities | 57,862 | (232,201 | ) | |||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from issuance of preferred stock, net | — | 51,902 | ||||||
| Proceeds from initial public offering, net of issuance cost | — | 244,316 | ||||||
| Proceeds from issuance of common stock related to stock purchase agreement | — | 13,638 | ||||||
| Proceeds from issuance of common stock | 503 | 1,252 | ||||||
| Payment of deferred offering cost | — | — | ||||||
| Net cash provided by financing activities | 503 | 311,108 | ||||||
| NET INCREASE (DECREASE) IN CASH | (18,139 | ) | 21,841 | |||||
| Cash, cash equivalents and restricted cash at beginning of year | 28,948 | 7,107 | ||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 10,809 | $ | 28,948 | ||||
| Reconciliation of cash, cash equivalents and restricted cash: | ||||||||
| Cash and cash equivalents | $ | 9,244 | $ | 27,383 | ||||
| Restricted cash | 1,565 | 1,565 | ||||||
| Total cash, cash equivalents and restricted cash | $ | 10,809 | $ | 28,948 | ||||
| Supplemental schedule of non-cash investing and financing activities: | ||||||||
| Vesting of unvested issued common stock | $ | 4 | $ | 123 | ||||
| Purchases of property and equipment included in accounts payable and accrued liabilities | $ | 8 | $ | 1,021 | ||||
| Deferred offering costs in accounts payable and accrued liabilities | $ | 102 | $ | — | ||||
| Right of use assets obtained in exchange for operating lease obligations | $ | 852 | $ | 14,657 | ||||
Investor Relations and Media Contacts:
Karen L. Bergman
Vice President, Communications and Investor Relations
Bolt Biotherapeutics, Inc.
650-665-9295
kbergman@boltbio.com
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com
David Melamed
Russo Partners, LLC
212-845-4271
david.melamed@russopartnersllc.com
